Role of neurotrophin-Trk interactions in oncology: The anti-tumor efficacy of potent and selective Trk tyrosine kinase inhibitors in pre-clinical tumor models
- Author
- RUGGERI, B. A1 ; MIKNYOCZKI, S. J1 ; SINGH, J1 ; HUDKINS, R. L1
[1] Cephalon, Inc., 145 Brandywine Parkway, West Chester, PA 19380, United States - Issue title
- ATP-site Directed Kinase Inhibitors for Therapeutic Intervention
- Author (monograph)
- HUDKINS, Robert L (Editor)1
[1] Cephalon, Inc., 145 Brandywine Parkway, West Chester, PA 19380-4245, United States - Source
Current medicinal chemistry. 1999, Vol 6, Num 9, pp 845-857 ; ref : 104 ref
- ISSN
- 0929-8673
- Scientific domain
- Biochemistry, molecular biology, biophysics; Pharmacology drugs
- Publisher
- Bentham Science, Schiphol
- Publication country
- Netherlands
- Document type
- Article
- Language
- English
- Keyword (fr)
- Animal Anticancéreux Chimiothérapie Composé aromatique Composé polycyclique Essai préclinique Homme Hétérocycle azote In vitro In vivo Inhibiteur enzyme Inhibition Lactame Neurotrophine Pancréas Pathologie expérimentale Prostate Protein-tyrosine kinase Rat Relation structure activité Récepteur biologique Souris Sélectivité Traitement Transduction signal Tumeur maligne CEP 2563 CEP 701 Indolo[2,3-a]pyrrolo[3,4-c]carbazol-5-one dérivé Indolopyrrolocarbazole KT 5555 KT 8391 Appareil digestif pathologie Appareil urinaire pathologie Enzyme Mammalia Rodentia Transferases Vertebrata
- Keyword (en)
- Animal Antineoplastic agent Chemotherapy Aromatic compound Polycyclic compound Preclinical trial Human Nitrogen heterocycle In vitro In vivo Enzyme inhibitor Inhibition Lactam Neurotrophin Pancreas Experimental disease Prostate Protein-tyrosine kinase Rat Structure activity relation Biological receptor Mouse Selectivity Treatment Signal transduction Malignant tumor Digestive diseases Urinary system disease Enzyme Mammalia Rodentia Transferases Vertebrata
- Keyword (es)
- Animal Anticanceroso Quimioterapia Compuesto aromático Compuesto policíclico Ensayo preclínico Hombre Heterociclo nitrógeno In vitro In vivo Inhibidor enzima Inhibición Lactamo Neurotrofina Páncreas Patología experimental Prostata Protein-tyrosine kinase Rata Relación estructura actividad Receptor biológico Ratón Selectividad Tratamiento Transducción señal Tumor maligno Aparato digestivo patología Aparato urinario patología Enzima Mammalia Rodentia Transferases Vertebrata
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R01 General aspects
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 1987642
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.2174/092986730609220401151459 
https://dx.doi.org/10.2174/092986730609220401151459
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2174\/092986730609220401151459\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:158:\"Role of neurotrophin-Trk interactions in oncology: The anti-tumor efficacy of potent and selective Trk tyrosine kinase inhibitors in pre-clinical tumor models\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Current medicinal chemistry\";s:9:\"\u0000*\u0000stitle\";s:15:\"Curr. med. chem\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:1:\"6\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:3:\"845\";s:8:\"\u0000*\u0000epage\";s:3:\"857\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0929-8673\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"RUGGERI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"B. A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:16:\"MIKNYOCZKI, S. J\";i:1;s:8:\"SINGH, J\";i:2;s:13:\"HUDKINS, R. L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:64:\"ATP-site Directed Kinase Inhibitors for Therapeutic Intervention\";s:8:\"\u0000*\u0000title\";s:158:\"Role of neurotrophin-Trk interactions in oncology: The anti-tumor efficacy of potent and selective Trk tyrosine kinase inhibitors in pre-clinical tumor models\";s:8:\"\u0000*\u0000place\";s:8:\"Schiphol\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2174\/092986730609220401151459\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:158:\"Role of neurotrophin-Trk interactions in oncology: The anti-tumor efficacy of potent and selective Trk tyrosine kinase inhibitors in pre-clinical tumor models\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Current medicinal chemistry\";s:9:\"\u0000*\u0000stitle\";s:15:\"Curr. med. chem\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:1:\"6\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:3:\"845\";s:8:\"\u0000*\u0000epage\";s:3:\"857\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0929-8673\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"RUGGERI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"B. A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:16:\"MIKNYOCZKI, S. J\";i:1;s:8:\"SINGH, J\";i:2;s:13:\"HUDKINS, R. L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:64:\"ATP-site Directed Kinase Inhibitors for Therapeutic Intervention\";s:8:\"\u0000*\u0000title\";s:158:\"Role of neurotrophin-Trk interactions in oncology: The anti-tumor efficacy of potent and selective Trk tyrosine kinase inhibitors in pre-clinical tumor models\";s:8:\"\u0000*\u0000place\";s:8:\"Schiphol\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:32:\"10.2174\/092986730609220401151459\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2174\/092986730609220401151459\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:158:\"Role of neurotrophin-Trk interactions in oncology: The anti-tumor efficacy of potent and selective Trk tyrosine kinase inhibitors in pre-clinical tumor models\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Current medicinal chemistry\";s:9:\"\u0000*\u0000stitle\";s:15:\"Curr. med. chem\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:1:\"6\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:3:\"845\";s:8:\"\u0000*\u0000epage\";s:3:\"857\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0929-8673\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"RUGGERI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"B. A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:16:\"MIKNYOCZKI, S. J\";i:1;s:8:\"SINGH, J\";i:2;s:13:\"HUDKINS, R. L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:64:\"ATP-site Directed Kinase Inhibitors for Therapeutic Intervention\";s:8:\"\u0000*\u0000title\";s:158:\"Role of neurotrophin-Trk interactions in oncology: The anti-tumor efficacy of potent and selective Trk tyrosine kinase inhibitors in pre-clinical tumor models\";s:8:\"\u0000*\u0000place\";s:8:\"Schiphol\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2174\/092986730609220401151459\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:158:\"Role of neurotrophin-Trk interactions in oncology: The anti-tumor efficacy of potent and selective Trk tyrosine kinase inhibitors in pre-clinical tumor models\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Current medicinal chemistry\";s:9:\"\u0000*\u0000stitle\";s:15:\"Curr. med. chem\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:1:\"6\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:3:\"845\";s:8:\"\u0000*\u0000epage\";s:3:\"857\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0929-8673\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"RUGGERI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"B. A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:16:\"MIKNYOCZKI, S. J\";i:1;s:8:\"SINGH, J\";i:2;s:13:\"HUDKINS, R. L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:64:\"ATP-site Directed Kinase Inhibitors for Therapeutic Intervention\";s:8:\"\u0000*\u0000title\";s:158:\"Role of neurotrophin-Trk interactions in oncology: The anti-tumor efficacy of potent and selective Trk tyrosine kinase inhibitors in pre-clinical tumor models\";s:8:\"\u0000*\u0000place\";s:8:\"Schiphol\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2174\/092986730609220401151459\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:158:\"Role of neurotrophin-Trk interactions in oncology: The anti-tumor efficacy of potent and selective Trk tyrosine kinase inhibitors in pre-clinical tumor models\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Current medicinal chemistry\";s:9:\"\u0000*\u0000stitle\";s:15:\"Curr. med. chem\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:1:\"6\";s:8:\"\u0000*\u0000issue\";s:1:\"9\";s:8:\"\u0000*\u0000spage\";s:3:\"845\";s:8:\"\u0000*\u0000epage\";s:3:\"857\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0929-8673\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"RUGGERI\";s:10:\"\u0000*\u0000aufirst\";s:4:\"B. A\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:3:{i:0;s:16:\"MIKNYOCZKI, S. J\";i:1;s:8:\"SINGH, J\";i:2;s:13:\"HUDKINS, R. L\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:64:\"ATP-site Directed Kinase Inhibitors for Therapeutic Intervention\";s:8:\"\u0000*\u0000title\";s:158:\"Role of neurotrophin-Trk interactions in oncology: The anti-tumor efficacy of potent and selective Trk tyrosine kinase inhibitors in pre-clinical tumor models\";s:8:\"\u0000*\u0000place\";s:8:\"Schiphol\";s:6:\"\u0000*\u0000pub\";s:15:\"Bentham Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
